#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Cataract Nephropathy Congenital pseudarthrosis Demyelination Phenylketonuria Burkitt's lymphoma Acromegaly Uterine leiomyosarcoma Mycobacterium abscessus infection Bulbospinal muscular atrophy congenital Bronchiolitis Aspergillus infection Drug eruption Fabry's disease More trials…

    Learn about Rare Diseases

    Pulmonary sarcoidosis – Diagnostics Marfan’s syndrome – Basic Information Uterine leiomyosarcoma Turner’s syndrome – Trials in Disease Piriformis syndrome – Diagnostics Mantle cell lymphoma stage III – Life with Disease Wolfram syndrome Anaplastic thyroid cancer – Life with Disease Optic glioma – Treatment Glycogen storage disease type II – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ibuprofen Lysine Estradiol Hemihydrate Oxytocin Emicizumab Briquilimab Brivaracetam ORG-129 Azelastine Brodalumab Ima402 SARACATINIB Sym024 SALICYLIC ACID Finasteride Opevesostat Tosilate Albumin Rilzabrutinib Cagrilintide Amcenestrant IADADEMSTAT More therapies…

    Learn about Your Condition

    Urticaria cholinergic Postoperative delirium Metastases to meninges Sexual dysfunction Hypopituitarism Head and neck cancer Hepatotoxicity Osteomyelitis Corneal graft rejection Bile duct cancer Incisional hernia Procedural hypotension Intestinal infarction Malignant neoplasm of choroid Liver disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Rhabdomyosarcoma

  • Indocyanine Green and Near-Infrared Fluorescence for Lymph Node Removal in Children with Renal Tumours or Paratesticular Rhabdomyosarcoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Indocyanine Green
    The Netherlands

  • Study on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • 1,3-BUTYLENE GLYCOL
    • Cinchocaine Hydrochloride
    • Patritumab Deruxtecan
    Belgium Czechia Denmark France Germany Greece +6

  • Study to Find the Right Dose and Safety of Lutetium (177Lu) Edotreotide and Arginine-Lysine in Children with Somatostatin Receptor-Positive Tumors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Central nervous system neoplasm
    • Neuroendocrine tumour
    • Peripheral primitive neuroectodermal tumour of soft tissue
    Investigated Drugs:
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    • Lutetium (177Lu) Edotreotide
    France Italy Spain

  • Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

    Recruiting

    3 1 1
    Investigated Drugs:
    • Ttf-Ngr
    Germany

  • Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Dactinomycin
    • Ifosfamide
    • Regorafenib
    Austria Belgium Czechia Denmark Finland France +10

  • Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Anaplastic large cell lymphoma T- and null-cell types
    • Inflammatory myofibroblastic tumour
    • Rhabdomyosarcoma
    Investigated Drugs:
    • Temsirolimus
    • Crizotinib
    Denmark Finland France Germany Italy The Netherlands +3
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!